Articles Brexit would be a blow for UK life sciences – regulators and... The British public is still split over Brexit – but pharma is warning of potentially serious consequences if the country votes 'Leave' on 23 June. Andrew McConaghie reports.
Views & Analysis An empowered patient means an empowered Europe Young Europeans are working together to suggest ways to manage health that will result in benefits to citizens and budgets.
Views & Analysis Obstacles to true patient centricity in Europe Campaigner and cancer patient Andrew Schorr says pharma needs to knock down the barriers to greater patient influence.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.